Analysts think CARM stock price could increase by 353%
May 07, 2025, 11:26 AM
-18.53%
What does CARM do
Carisma Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing immunotherapies for solid tumors, including CAR-M therapies CT-0508 and CT-0525. The company went public in February 2014 and employs 107 people.
4 analysts think CARM stock price will increase by 353.13%. The current median analyst target is $1.02 compared to a current stock price of $0.23. The lowest analysts target is $1.01 and the highest analyst target is $1.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
